Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout (MIRROR RCT)

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving KRYSTEXXA® (Pegloticase) (MIRROR Randomized Controlled Trial [RCT])

The purpose of this study is to assess the potential for pegloticase with methotrexate (MTX) to increase the response rate seen with pegloticase alone, and to characterize the safety, tolerability and pharmacokinetics (PK) of the concomitant use of pegloticase with MTX, by comparing pegloticase co-administered with MTX to pegloticase co-administered with placebo for MTX in adults with uncontrolled gout.

Study Overview

• Status: Completed
• Conditions: Gout
• Intervention / Treatment: Biological: Pegloticase; Drug: methotrexate; Dietary supplement: folic acid; Drug: gout flare prophylaxis regimen; Drug: fexofenadine; Drug: acetaminophen; Drug: methylprednisolone; Drug: placebo

• Study Type: Interventional
• Enrollment (Actual): 152
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • University of Alabama
  • Alaska
    • Anchorage, Alaska, United States, 99508
      • Orthopedic Physicians Alaska
  • Arizona
    • Flagstaff, Arizona, United States, 86001
      • Arizona Arthritis and Rheumatology Research, PLLC - Flagstaff
    • Glendale, Arizona, United States, 85306
      • Arizona Arthritis and Rheumatology Research, PLLC-West
    • Mesa, Arizona, United States, 85210
      • Arizona Arthritis and Rheumatology Research, PLLC-East
  • Arkansas
    • Little Rock, Arkansas, United States, 72212
      • Applied Research Center of Arkansas, Inc
  • California
    • El Cajon, California, United States, 92020
      • Triwest Research Associates
    • Hawthorne, California, United States, 90250
      • Advanced Investigative Medicine, Inc.
    • Los Angeles, California, United States, 90036
      • Axis Clinical Trials
    • Poway, California, United States, 92064
      • ACRC Studies
    • Roseville, California, United States, 95661
      • ClinEdge Sierra Rheumatology, Inc.
    • San Leandro, California, United States, 94578
      • East Bay Rheumatology Medical Group, Inc.
    • Santa Monica, California, United States, 90404
      • Providence St. John's Health Clinic
    • Tujunga, California, United States, 91042
      • Medvin Clinical Research
    • Van Nuys, California, United States, 91405
      • San Fernando Valley Health Institute
    • Ventura, California, United States, 93003
      • Ventura Clinical Trials
  • Colorado
    • Aurora, Colorado, United States, 80045
      • University of Colorado Division of Rheumatology
    • Denver, Colorado, United States, 80230
      • Denver Arthritis Clinic
  • Florida
    • DeLand, Florida, United States, 32720
      • Avail Clinical Research
    • Doral, Florida, United States, 33166
      • Prohealth Research Center
    • Orlando, Florida, United States, 32808
      • Omega Research Maitland
    • Pinellas Park, Florida, United States, 33782
      • DMI Research
    • Pompano Beach, Florida, United States, 33064
      • Napa Research Center
    • Tampa, Florida, United States, 33609
      • GCP Clinical Research
    • Zephyrhills, Florida, United States, 33542
      • Florida Medical Clinic, LLC
  • Idaho
    • Meridian, Idaho, United States, 83642
      • St. Luke's Clinic - Rheumatology
  • Maryland
    • Oxon Hill, Maryland, United States, 20745
      • MD Medical Research
    • Wheaton, Maryland, United States, 20902
      • The Center for Rheumatology and Bone Research
  • Michigan
    • Grand Rapids, Michigan, United States, 49525
      • Infusion Associates
    • Saint Clair Shores, Michigan, United States, 48081
      • Clinical Research Institute of Michigan, LLC
  • Montana
    • Great Falls, Montana, United States, 59405
      • Benefis Hospital
  • Nebraska
    • Lincoln, Nebraska, United States, 68516
      • Physician Research Collaboration, LLC
  • New Mexico
    • Santa Fe, New Mexico, United States, 87505
      • Santa Fe Rheumatology
  • New York
    • Babylon, New York, United States, 11702
      • Long Island Arthritis & Osteoporosis Care
    • Orchard Park, New York, United States, 14127
      • Buffalo Rheumatology and Medicine
  • North Carolina
    • Concord, North Carolina, United States, 28025
      • NorthEast Rheumatology
    • Concord, North Carolina, United States, 28025
      • NorthEast Rheumatology/Atrium Health
    • Greensboro, North Carolina, United States, 27408
      • Medication Management, LLC
    • Hickory, North Carolina, United States, 28602
      • ClinEdge PMG Research of Hickory, LLC
    • Salisbury, North Carolina, United States, 28144
      • ClinEdge PMG Research of Salisbury, LLC
    • Shelby, North Carolina, United States, 28150
      • Shelby Clinical Research, LLC
    • Wilmington, North Carolina, United States, 28401
      • PMG Research of Wilmington, LLC
  • Ohio
    • Dayton, Ohio, United States, 45417
      • Premier Clinical/STAT Research
    • Middleburg Heights, Ohio, United States, 44130
      • Paramount Medical Research & Consulting, LLC
    • Perrysburg, Ohio, United States, 43551
      • Clinical Research Source Inc.
    • Springboro, Ohio, United States, 45066
      • Premier Clinical/STAT Research - Springboro
  • Pennsylvania
    • Duncansville, Pennsylvania, United States, 16635
      • Altoona Center for Clinical Research
  • South Carolina
    • Greenville, South Carolina, United States, 29601
      • Piedmont Arthritis Clinic
    • Summerville, South Carolina, United States, 29486
      • Articularis Healthcare Group
  • Tennessee
    • Jackson, Tennessee, United States, 38305
      • West Tennessee Research Institute
    • Memphis, Tennessee, United States, 38119
      • Ramesh C. Gupta, M.D.
  • Texas
    • Houston, Texas, United States, 77004
      • Diagnostic and Interventional Nephrology Of Houston
    • Houston, Texas, United States, 77024
      • Research Consultants - Frostwood
    • Houston, Texas, United States, 77089
      • Research Consultants - Astoria
    • San Marcos, Texas, United States, 78666
      • Arthritis Clinic of Central Texas
    • Waco, Texas, United States, 76710
      • Arthritis & Osteoporosis Clinic - Waco
    • Webster, Texas, United States, 77598
      • Clear Lake Specialties
  • Washington
    • Bothell, Washington, United States, 98021
      • Western Washington Arthritis Clinic
    • Spokane, Washington, United States, 99204
      • Arthritis Northwest
  • Wisconsin
    • Glendale, Wisconsin, United States, 53219
      • Rheumatic Disease Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Willing and able to give informed consent.
2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.
3. Adult men or women ≥18 years of age.

4. Uncontrolled gout, defined as meeting the following criteria:

   • Hyperuricemia during the screening period defined as sUA ≥7 mg/dL, and;
   • Failure to maintain normalization of sUA with xanthine oxidase inhibitors at the maximum medically appropriate dose, or with a contraindication to xanthine oxidase inhibitor therapy based on medical record review or subject interview, and;

   • Symptoms of gout including at least 1 of the following:

     • Presence of at least one tophus
     • Recurrent flares defined as 2 or more flares in the past 12 months prior to screening
     • Presence of chronic gouty arthritis
5. Willing to discontinue any oral urate lowering therapy for at least 7 days prior to MTX dosing at Week -6 and remain off when receiving pegloticase infusions.
6. Women of childbearing potential (including those with an onset of menopause <2 years prior to screening, non-therapy-induced amenorrhea for <12 months prior to screening, or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum/urine pregnancy tests during Screening and Week -6; subjects must agree to use 2 reliable forms of contraception during the study, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -6 (start of MTX) and continue for 30 days after the last dose of pegloticase, or at least one ovulatory cycle after the last dose of MTX or placebo for MTX (whichever is the longest duration after the last dose of pegloticase or MTX or placebo for MTX). Highly effective contraceptive methods (with a failure rate <1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
7. Men who are not vasectomized must agree to use appropriate contraception so as to not impregnate a female partner of reproductive potential during the study, beginning with the initiation of MTX at Week -6 and continuing and for at least 3 months after the last dose of MTX or placebo for MTX.
8. Able to tolerate MTX 15 mg orally for 2 weeks (Week -6 through Week -4) prior to randomization.

Exclusion Criteria:

1. Weight >160 kg (352 pounds) at Screening.
2. Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Week -6 Visit.
3. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
4. Current or chronic treatment with systemic immunosuppressive agents such as MTX, azathioprine, or mycophenolate mofetil; prednisone ≥10 mg/day or equivalent dose of other corticosteroid on a chronic basis (3 months or longer) would also meet exclusion criteria.
5. History of any transplant surgery requiring maintenance immunosuppressive therapy.
6. Known history of hepatitis B virus surface antigen positivity or hepatitis B DNA positivity.
7. Known history of hepatitis C virus ribonucleic acid (RNA) positivity.
8. Known history of Human Immunodeficiency Virus (HIV) positivity.
9. Glucose-6-phosphate dehydrogenase deficiency (tested at the Screening Visit).
10. Chronic renal impairment defined as estimated glomerular filtration rate (eGFR) < 40 mL/min/1.73 m^2 or currently on dialysis.
11. Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (>160/100 mmHg) prior to Randomization at Week -4.
12. Pregnant, planning to become pregnant, breastfeeding, planning to impregnate female partner, or not on an effective form of birth control, as determined by the Investigator.
13. Prior treatment with pegloticase, another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
14. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
15. Contraindication to MTX treatment or MTX treatment considered inappropriate.
16. Known intolerance to MTX.
17. Receipt of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -6 or plans to take an investigational drug during the study.
18. Liver transaminase levels (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) > upper limit of normal (ULN) or albumin < the lower limit of normal (LLN) at the Screening Visit).
19. Chronic liver disease.
20. White blood cell count < 4,000/µL, hematocrit < 32 percent, or platelet count < 75,000/µL.
21. Currently receiving systemic or radiologic treatment for ongoing cancer.
22. History of malignancy within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
23. Diagnosis of osteomyelitis.
24. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
25. Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements or complete the study.
26. Alcohol use in excess of 3 alcoholic beverages per week.
27. A known intolerance to all protocol standard gout flare prophylaxis regimens (i.e. subject must be able to tolerate at least one: colchicine and/or non-steroidal anti inflammatory drugs and/or low dose prednisone ≤10 mg/day).
28. Current pulmonary fibrosis, bronchiectasis or interstitial pneumonitis. If deemed necessary by the Investigator, a chest X-ray may be performed during Screening.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Pegloticase + MTX; Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral MTX 15 mg weekly during the Run-in Period (from Week -4 to Day 1). During the Pegloticase + Immunomodulator (IMM) Period, in addition to oral 15 mg MTX, participants receive intravenous (IV) pegloticase 8 mg administered every 2 weeks (Q2W) for a total of 26 infusions from Day 1 through the Week 50 Visit. Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for infusion reaction (IR) prophylaxis.	Biological: Pegloticase; IV pegloticase 8 mg Q2W; Other Names: KRYSTEXXA®; Drug: methotrexate; Oral MTX 15 mg weekly; Other Names: MTX; Dietary supplement: folic acid; Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.; Drug: gout flare prophylaxis regimen; Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines [Khanna D et al. 2012] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA < 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA < 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.; Drug: fexofenadine; For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.; Drug: acetaminophen; For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.; Drug: methylprednisolone; For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
Placebo Comparator: Pegloticase + Placebo; Following the MTX Tolerability Assessment Period (Week -6 until the Week -4 visit, in which participants take oral MTX 15 mg weekly), participants tolerating MTX are randomized to receive blinded oral placebo for MTX weekly during the Run-in Period (from Week -4 to Day 1). During the Pegloticase + IMM Period, in addition to oral placebo for MTX, all participants receive IV pegloticase 8 mg administered Q2W for a total of 26 infusions from Day 1 through the Week 50 Visit. Per protocol, participants are also required to take folic acid, at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day), and a regimen of fexofenadine, acetaminophen, and methylprednisolone for IR prophylaxis.	Biological: Pegloticase; IV pegloticase 8 mg Q2W; Other Names: KRYSTEXXA®; Drug: methotrexate; Oral MTX 15 mg weekly; Other Names: MTX; Dietary supplement: folic acid; Folic acid 1 mg orally every day beginning at Week -6 until prior to the Week 52 Visit.; Drug: gout flare prophylaxis regimen; Prior to beginning the Pegloticase + IMM Period, participants must have been taking at least 1 protocol-standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤ 10 mg/day) for ≥ 1 week before the first dose of pegloticase and to continue flare prophylaxis per American College of Rheumatology guidelines [Khanna D et al. 2012] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA < 6 mg/dL) for participants with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA < 5 mg/dL) for participants with one or more tophi detected on initial physical exam that then resolved.; Drug: fexofenadine; For IR prophylaxis, fexofenadine (180 mg orally) taken the day before each infusion and on the morning of each infusion.; Drug: acetaminophen; For IR prophylaxis, acetaminophen (1000 mg orally) taken the morning of each infusion.; Drug: methylprednisolone; For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.; Drug: placebo; Oral placebo for MTX

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Serum Uric Acid (sUA) Responders (sUA < 6 mg/dL) During Month 6	Responders are defined as participants achieving and maintaining sUA < 6 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre- and post-infusion sUA assessments at Weeks 20 and 22, non-infusion sUA at Weeks 21 and 23, pre-infusion sUA at Week 24 and any unscheduled sUA between Week 20 and Week 24. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA >6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders.	Month 6 (Weeks 20, 21, 22, 23 and 24)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Participants With Complete Resolution of ≥ 1 Tophi at Week 52	Percentage of participants with complete resolution of ≥ 1 tophi (using digital photography) at Week 52 in participants with tophi at baseline. Participants with resolution of ≥ 1 tophi at a visit are participants with resolution of ≥ 1 tophi at the visit (i.e. have complete response), and no progressive disease for any other tophi.	Baseline, Week 52
Mean Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 52	HAQ-DI is a self-report functional status instrument that is filled out by the participant and measures disability over the past week via 20 questions relating to 8 domains of function: dressing, grooming, arising, eating, walking, hygiene, reach, grip, and usual activities. The HAQ-DI ranges from 0 to 3 with higher values indicating higher disability. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.	Baseline, Week 52
Percentage of sUA (sUA < 6 mg/dL) Responders During Month 12	Responders are defined as participants achieving and maintaining sUA <6 mg/dL for at least 80% of the time during Month 12 (Weeks 48, 50 and 52). Month 12 includes pre- and post-infusion sUA Weeks 48 and 50, pre-infusion sUA at Week 52, and any unscheduled sUA assessments done at unscheduled visits between Week 48 and 52. A participant must have had ≥ 2 sUA observations from different visits in order to be eligible as a responder. Participants meeting the stopping rule (those with a pre-infusion sUA >6 mg/dL at 2 consecutive scheduled trial visits beginning with the Week 2 Visit stopped pegloticase dosing) were counted as non-responders.	Month 12 (Weeks 48, 50 and 52)
Mean Change From Baseline HAQ Pain Score at Week 52	The HAQ-Pain score rates the participant's pain over the past week from 0 to 100 with 0 = no pain and 100 = severe pain. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.	Baseline, Week 52
Mean Change From Baseline in HAQ Health Score at Week 52	The HAQ health scale is a self-reported measure of overall health. Participants are asked to rate how they are doing, considering all the ways arthritis affects them, on a scale of 0 to 100, where 0 represents very well and 100 represents very poor. A change from baseline value of 0 is imputed at the first post-baseline visit for any participants without post-baseline values.	Baseline, Week 52

Collaborators and Investigators

• Sponsor: Horizon Therapeutics Ireland DAC
• Investigators: Study Director: Study Director, Horizon Therapeutics USA, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): June 13, 2019
• Primary Completion (Actual): March 17, 2021
• Study Completion (Actual): April 11, 2022

Study Registration Dates

• First Submitted: June 19, 2019
• First Submitted That Met QC Criteria: June 19, 2019
• First Posted (Actual): June 21, 2019

Study Record Updates

• Last Update Posted (Actual): March 21, 2023
• Last Update Submitted That Met QC Criteria: February 21, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: gout; uncontrolled gout
• Additional Relevant MeSH Terms: Metabolic Diseases; Genetic Diseases, Inborn; Joint Diseases; Musculoskeletal Diseases; Rheumatic Diseases; Arthritis; Metabolism, Inborn Errors; Crystal Arthropathies; Purine-Pyrimidine Metabolism, Inborn Errors; Gout; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Nucleic Acid Synthesis Inhibitors; Enzyme Inhibitors; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Antipyretics; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antiemetics; Gastrointestinal Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Neuroprotective Agents; Protective Agents; Dermatologic Agents; Micronutrients; Vitamins; Reproductive Control Agents; Anti-Allergic Agents; Vitamin B Complex; Hematinics; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Abortifacient Agents, Nonsteroidal; Abortifacient Agents; Folic Acid Antagonists; Histamine H1 Antagonists, Non-Sedating; Methylprednisolone; Acetaminophen; Methotrexate; Folic Acid; Fexofenadine
• Other Study ID Numbers: HZNP-KRY-202

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No